Method of treating diseases associated with LRRK2 mutation using hexachlorophene
AssigneeUniversity of South Florida
InventorsUmesh K. Jinwal, Malathi Narayan
Life of this patent
Estimating the term…
Abstract
A method of treating a disease associated with mutation of LRRK2 protein is presented herein. It was found that administering hexachlorophene to cells expressing endogenous LRRK2 or overexpressing wild-type or mutant LRRK2 reduced the total LRRK2 level in the cells.
Claims12
A method of treating a disease characterized by mutation of LRRK2 protein in a patient in need thereof comprising administering a therapeutically effective amount of hexachlorophene, wherein the hexachlorophene is administered concomitantly with a drug selected from the group consisting of withaferin A and celastrol.
A method of reducing LRRK2 protein expression levels in a cell comprising contacting the cell with a therapeutically effective amount of hexachlorophene, further comprising administering a Hsp90 inhibitor concomitantly with the hexachlorophene, wherein the Hsp90 inhibitor is selected from withaferin A (WA) and celastrol.
A method of inhibiting LRRK2 activity in a cell comprising contacting the cell with a therapeutically effective amount of hexachlorophene, further comprising administering a Hsp90 inhibitor concomitantly with the hexachlorophene, wherein the Hsp90 inhibitor is selected from withaferin A (WA) and celastrol.
Dependencies are inferred from the claim text.